Bach Pharma, Inc., (BACH), a privately held pharmaceutical company which is developing new therapeutics for the treatment of neurodegenerative diseases like ALS and Parkinson’s and other life-threatening redox regulation-related illnesses. These are revolutionary phthalazinedione-based therapeutics who's goal is to dramatically improve patients' lives and reduce the cost of global health care.
The company's lead candidate, GVT®, is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties. GVT has shown significant effects pre-clinically to reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. GVT has the potential to treat serious diseases of the central nervous and immune systems as many are associated with oxidative stress and inflammatory pathways. The leading program will be focused on severe rare neurological diseases such as amyotrophic lateral sclerosis (ALS).
BACH maintains one of the world's most active monosodium luminol (MSL) research programs. The company was first founded to support improved manufacturing of Galavit®, a monosodium luminol product marketed in Russia. Galavit has demonstrated a strong safety profile in Russian clinical trials. GVT is a highly purified version of monosodium luminol with scaled up manufacturing processes.
With the addition of new management at the board and executive level, BACH is now focused on bringing GVT to the clinical for serious degenerative diseases.